Chandra P. Belani, MD, discusses CO-1686, which is currently being studied for the treatment of non-small cell lung cancer.
Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses CO-1686, which is currently being studied for the treatment of non-small cell lung cancer (NSCLC).
Belani says CO-1686 targets the EGFR mutation as well as T790M mutations, which causes resistance to EGFR-directed therapies. Belani says this drug has not reached its maximum tolerated dose. Doses up to 900mg BID have been given during the study.
Halfway through the study, the formation was changed because the hydrobromide salt tablet formulation of the agent was found to be more effective pharmaceutically and did not have any effect on wild-type EGFR. Belani says this reduced the side effects of rash and diarrhea.
The impressive activity of this agent has been seen in patients with T790M mutations, with an overall response rate of 67%, Belani says.
Belani says there is currently a phase I study of this agent in the Japanese population and more data will be available in the near future.